Orpheus BioScience

Orpheus Bioscience is a preclinical-stage biotechnology company specializing in precision medicine for autoimmune and inflammatory disorders, particularly systemic lupus erythematosus (SLE). The company utilizes a proprietary platform that integrates high-dimensional transcriptomics and single-cell analysis to deconstruct the molecular heterogeneity of autoimmune diseases. By identifying specific patient endotypes and disease-driving pathways, Orpheus develops targeted therapies designed to improve clinical outcomes over traditional broad-spectrum immunosuppressants. The leadership team consists of world-renowned experts in immunology who have been instrumental in large-scale research initiatives like the Accelerating Medicines Partnership (AMP). Their approach aims to deliver the right drug to the right patient at the right time in the autoimmune space.